This was the stock's third consecutive day of gains.
Zoetis' Q4 earnings met expectations, but the stock fell due to slowing growth and cautious 2025 guidance. Click here to find ...
BTIG lowered the firm’s price target on Zoetis (ZTS) to $200 from $225 and keeps a Buy rating on the shares. The company delivered an in-line ...
Zoetis slightly topped analyst estimates for profitability and met those for revenue in its fourth quarter. But as investors ...
Zoetis received a USDA conditional license for its H5N2 avian flu vaccine for chickens, marking a step in addressing the ...
Phibro Animal Health projects strong 2025 revenue growth despite debt concerns. Read this artile to know why I think PAHC ...
Zoetis exceeded market expectations in Q4 2024, with impressive financial performance despite challenges in specific segments ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results